Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis

Investigational once-weekly efanesoctocog alfa prophylaxis met the primary efficacy endpoint providing clinically meaningful bleed protection for people with severe hemophilia AResults underscore the ability of efanesoctocog alfa to sustain normal to near-normal factor levels and the potential to transform prophylac...

Related Keywords

Stockholm ,Sweden ,United States ,Paris ,France General ,France ,Russia ,America ,Eva Schaefer Jansen ,Corentine Driancourt ,Felix Lauscher ,Anders Ullman ,Kate Conway ,Nathalie Pham ,Sandrine Guendoul ,Dietmar Berger ,Sally Bain ,Priya Nanduri ,Linkedin ,Global Head Of Development ,International Society On Thrombosis ,European Commission ,Drug Administration ,Nasdaq ,Youtube ,Thrombosis Treatment Center ,Euronext ,Swedish Orphan Biovitrum ,International Society ,Chief Medical Officer ,Breakthrough Therapy Designation ,Fast Track ,Orphan Drug ,Biologics License Application ,North Africa ,Middle Eastern ,North America ,Middle East ,Sobi Media ,